Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.82 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.66 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135913 | 0.91 | GRM3 (1.00) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5060080 | 0.84 | GRM3 (0.85) | GRM3FOLH1NAALAD2 | |
| SCHEMBL18647063 | 0.82 | GRM3 (0.82) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5060255 | 0.82 | GRM3 (0.82) | GRM3FOLH1NAALAD2 | |
| SCHEMBL20529841 | 0.81 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5051325 | 0.81 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5053371 | 0.81 | GRM3 (0.79) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1278279 | 0.80 | FOLH1 (1.00) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1377500 | 0.80 | GRM3 (0.79) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1376163 | 0.80 | GRM3 (0.79) | GRM3FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150079001-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-19 | — | — | US | disclosed |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | GEORGETOWN UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-8227634-B2 | Imaging agents and methods of imaging NAALADase or PSMA | POMPER MARTIN GILBERT (US) | 2012-07-24 | — | — | US | disclosed |
| EP-1472541-B1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OF PSMA | UNIV JOHNS HOPKINS (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-7408079-B2 | Imaging prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1472541-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OF PSMA | The Johns Hopkins University (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040054190-A1 | Imaging prostate cancer | JOHNS HOPKINS UNIVERSITY | 2004-03-18 | — | — | US | disclosed |
| WO-2003060523-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OF PSMA | JOHNS HOPKINS UNIVERSITY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054190-A1 | Imaging prostate cancer | FOLH1, DUT, NAALAD2 | GRM3 3266/4885FOLH1 1/4885NAALAD2 3/4885 |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | FOLH1, DNPEP, NAALAD2 | GRM3 3274/4885FOLH1 1/4885NAALAD2 3/4885 |
| US-20150079001-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | GRM3 3274/4885FOLH1 1/4885NAALAD2 3/4885 |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | GRM3 3274/4885FOLH1 1/4885NAALAD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.